Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AstraZeneca HDAC6 compound 15
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules
01
Overview
AstraZeneca HDAC6 compound 15: sourced facts only. name: "Compound 15 exhibited selective HDAC6 degradation with subnanomolar degradation potency in bronchial epithelium cells, effectively inducing α-tubulin hyperacetylation without affecting histone-3 acetylation." [PMID:42305196]; target: "Compound 15 exhibited selective HDAC6 degradation with subnanomolar degradation potency in bronchial epithelium cells, effectively inducing α-tubulin hyperacetylation without affecting histone-3 acetylation." [PMID:42305196]; developer: "†Respiratory & Immunology, ‡Discovery Sciences, §Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, 43183 Mölndal, Sweden." [PMID:42305196]; modality: "We report the discovery and characterization of a novel HDAC6 degrader, compound 15, designed by conjugating a selective hydroxamic acid HDAC6 inhibitor (2) to a cereblon-recruiting ligand via a short, rigid linker." [PMID:42305196]
02
Targets
HDAC6 (Histone deacetylase 6)
Beyond the preview
Go deeper on AstraZeneca HDAC6 compound 15.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AstraZeneca HDAC6 compound 15.